In view of the common characteristics of the pathological mechanisms of cancer and fibrosis, anti-tumour drugs that inhibit SUMOylation of TGF-β pathway components may be used when certain organs begin to undergo fibrosis [151]. The gene discussed is TGFB1; the disease is neoplasm.